Brain Cancers Forum on Glioblastoma &
Diffuse Intrinsic Pontine Glioma Forum
SYDNEY, May 25, 2023
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX:
KZA), an oncology-focused drug development company, has been
invited to the White House to participate in the Cancer
Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse
Intrinsic Pontine Glioma (DIPG), to be held
on Thursday, 25 May 2023.
In alignment with President Joe
Biden and First Lady Dr. Jill
Biden's commitment to end cancer, the forum will bring
together patients, caregivers, oncologists, researchers, and
government officials to discuss and spur action against rare adult
and pediatric cancers.
Forum participants will discuss strategies to improve outcomes
for GBM and DIPG patients, share progress in research and drug
development, learn about efforts to accelerate progress, and
generate commitments for further action. Kazia's CEO, Dr.
John Friend, was invited and will be
participating in this forum.
The invitation for Dr. Friend to participate in the forum
reflects the importance of Kazia's work in developing treatments
for GBM and DIPG and reconfirms Kazia's position as a global leader
in this field.
"We are honored to participate in the Cancer Moonshot forum on
adult and pediatric brain cancer alongside global Neuro-Oncology
thought leaders, researchers, US government officials and patient
advocates," stated Dr. Friend. "Kazia is uniquely positioned to add
tremendous value to the discussion because our lead clinical asset,
paxalisib, is currently engaged in a number of brain tumor studies,
including GBM and DIPG."
GBM is the most aggressive and most common primary brain cancer
with a five-year survival rate of approximately 10%. Current
therapies are limited to surgery, radiation and traditional
chemotherapy. Kazia partnered with the Global Coalition for
Adaptive Research in 2021 to evaluate paxalisib in an adaptive
platform trial (GBM AGILE, NCT03970447) for which data is
anticipated in 2023.
DIPG is a rare childhood tumor of the brain. There is
currently no FDA-approved therapy for the disease, and median
survival is just 9-11 months from diagnosis. Kazia partnered with
the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to evaluate
paxalisib and ONC201 in an adaptive platform phase II trial
(NCT05009992). Data from the study is anticipated in 2023.
In addition to GBM and DIPG, Kazia is currently supporting three
US-based clinical studies to explore paxalisib for the treatment of
tumor metastasis in the brain as well as several pre-clinical
research collaborations to elucidate additional targeted treatment
strategies for paxalisib in other tumor types. Results from these
collaborations have been presented at the 2022 and 2023 meetings
for the American Association for Cancer Research and 2022 meeting
for the Society for Melanoma Research.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K/Akt/mTOR pathway, which is being developed to treat
multiple forms of brain cancer. Licensed from Genentech in late
2016, paxalisib is or has been the subject of ten clinical trials
in this disease. A completed phase II study in glioblastoma
reported promising signals of efficacy in 2021, and a pivotal study
for registration, GBM AGILE, is ongoing, with final data expected
in CY2023. Other clinical trials are ongoing in brain metastases,
diffuse midline gliomas, and primary CNS lymphoma, with several of
these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma
by the US FDA in February 2018, and
Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib
was granted Rare Pediatric Disease Designation and Orphan
Designation by the US FDA for DIPG in August
2020, and for atypical teratoid/rhabdoid tumors (AT/RT) in
June 2022 and July 2022, respectively. Kazia is also developing
EVT 801, a small-molecule inhibitor of VEGFR3, which was licensed
from Evotec SE in April 2021.
Preclinical data has shown EVT801 to be active against a broad
range of tumor types and has provided compelling evidence of
synergy with immuno-oncology agents. A phase I study commenced
recruitment in November 2021.
Forward-Looking Statements
This announcement may contain forward-looking statements, which
can generally be identified as such by the use of words such as
"may," "will," "estimate," "future," "forward," "anticipate," or
other similar words. Any statement describing Kazia's future plans,
strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are
also forward-looking statements, including, but not limited to,
statements regarding: the timing for results and data related to
Kazia's clinical and preclinical trials, and Kazia's strategy and
plans with respect to its programs, including paxalisib and EVT801.
Such statements are based on Kazia's current expectations and
projections about future events and future trends affecting its
business and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those
anticipated in the forward-looking statements, including risks and
uncertainties: associated with clinical and preclinical trials and
product candidate development, related to regulatory approvals,
related to our collaborations with third parties , and related to
the impact of global economic conditions, including disruptions in
the banking industry. These and other risks and uncertainties are
described more fully in Kazia's Annual Report, filed on form 20-F
with the SEC, and in subsequent filings with the SEC. Kazia
undertakes no obligation to publicly update any forward- looking
statement, whether as a result of new information, future events,
or otherwise, except as required under applicable law. You should
not place undue reliance on these forward-looking statements, which
apply only as of the date of this announcement.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
John Friend, Chief Executive
Officer.
For More Information, Please Contact:
Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-ceo-dr-john-friend-to-participate-in-white-house-cancer-moonshot-301834060.html
SOURCE Kazia Therapeutics Limited